Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
As binary events go, they don't get much bigger than decisions on Food and Drug Administration marketing applications. They can change the fortunes of a company in the blink of an eye, or at least however long it takes to read the letter from the FDA.
Imagine how different MannKind's (Nasdaq: MNKD ) 2011 would have been if it had gotten its inhaled insulin Afrezza approved in January. This article would be about whether the company was hitting its sales figures.
Instead MannKind ends the year down 66%, even more if you measure from the peak of the run-up into the FDA decision.
http://www.fool.com/investing/high-growth/2011/12/27/2011-no-dreamboat-for-mannkind.aspx
Imagine how different MannKind's (Nasdaq: MNKD ) 2011 would have been if it had gotten its inhaled insulin Afrezza approved in January. This article would be about whether the company was hitting its sales figures.
Instead MannKind ends the year down 66%, even more if you measure from the peak of the run-up into the FDA decision.
http://www.fool.com/investing/high-growth/2011/12/27/2011-no-dreamboat-for-mannkind.aspx